Medicare drug price negotiations lowered out-of-pocket costs for some beneficiaries, but those reaching the annual Part D cap saw no direct savings.
|Articles|April 16, 2012
Medicare To Tie Doctors' Pay To Quality, Cost Of Care
Advertisement
Twenty thousand physicians in four Midwest states received a glimpse into their financial future last month. Landing in their e-mail inboxes were links to
Read the full story:
Source: Kaiser Health News
Advertisement
Related to this article
Medicaid expansion was associated with lower colorectal cancer mortality, with the largest reductions in Hispanic patients and stage IV disease.
Amanda Velazquez, MD, discusses GLP-1 formulary strategies, overcoming prior authorization hurdles, and building scalable obesity care infrastructure.
Older adults on Medicare report the best access to care among 10 countries but more cost-related problems and higher out-of-pocket spending.
Even when physicians prescribe guideline-preferred therapies, step therapy and prior authorization can delay or restrict access to CLL therapies.
The trade group says CMS lacks authority to impose GLOBE, which is set to begin January 1.
AI quantitative CT (UCLA QILD, Brainomix e-Lung) predicts FVC decline and drug response in PPF, strengthening biomarkers beyond spirometry in INBUILD.
Delphi consensus guides dermatology on spotting CTCL vs atopic dermatitis before/after dupilumab, using biopsy plus T-cell clonality testing and safer treatment switches.
Advertisement
Advertisement
Trending on AJMC
1
A New Mechanism for DME in the BRUNELLO Trial: Donald J. D’Amico, MD
2
Using Complement Inhibitors in GA Comes With Pros and Cons
3
Pairing VYD2311 With mRNA COVID-19 Vaccines: Michael Mina, MD, PhD
4
New Mechanism of DME Treatment Highlights Clinical Trial Updates
5